Orca Bio

Orca Bio is a late-stage biotechnology company based in Menlo Park, California, with a manufacturing facility in Sacramento. Founded in 2016, the company specializes in high-precision, allogeneic cell therapies aimed at treating cancer, particularly blood cancers like acute myeloid leukemia and acute lymphocytic leukemia, as well as autoimmune diseases and genetic blood disorders. The company's mission is to redefine allogeneic stem cell transplants by delivering purified cell therapies that enhance survival rates and reduce risks associated with transplants. Orca Bio's lead investigational therapy, Orca-T, is currently in a pivotal Phase 3 trial and has received several designations from the FDA, including Regenerative Medicine Advanced Therapy. The company also focuses on developing additional therapies for various blood and immune disorders, supported by a state-of-the-art manufacturing facility capable of producing thousands of cell therapy products annually.

Pharmaceuticals Menlo Park, United States ~375 employees Private · Series D

Work at Orca Bio in HR or recruiting? Claim this page

Employees
375
+10% in the 3 months to Sep 2026
Revenue / employee
$128K
Revenue ~$48M
Total funding
$192M
Last round Series D, Jun 2020
12-month attrition
9%
Tech: 5.1%
H1B sponsor
NA
Open jobs
12
Last 30 days

Headcount trend

Orca Bio went from 148 employees in Oct 2024 to 375 in Sep 2026. Apr to Sep 2026: 104 people joined, 16 left.

Funding rounds

Total funding$192M
Funding rounds4
Investors7
DateRoundMoney raisedNo.Investors
Jun 2020Series D$192M7
May 2018Series C–1
Jan 2017Seed–––
May 2016Seed–––

Org structure

Headcount by department

Other185
Operations118
Engineering48
Finance9
Marketing4
HR4
Sales3
Success2

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.